Hospital MobilityINTOMOBNCT05639231
An INtervention TO Improve MOBility of Older Hospitalized Patients
A study testing INTOMOB intervention in people with Hospital Mobility and Mobility Limitation, run by Insel Gruppe AG, University Hospital Bern at 4 sites in Switzerland.
Trial summary
Low mobility during an acute care hospitalization is very frequent, particularly among older patients, and associated with adverse outcomes, such as persistent functional decline, institutionalization and death. However, increasing hospital mobility remains challenging because of the multiple existing barriers. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Hospital Mobility, Mobility Limitation, Life-Space
- What is being tested?
- INTOMOB intervention
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 383 participants
- Where
- 4 sitesSwitzerland
- Study dates
- 15 Dec 2022to 18 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Admission to a general internal medicine (GIM) ward of a participating hospital
- Age ≥60 years
- Being ambulatory during the 2 weeks before admission (self-report)
- Living in the community (not in a nursing home or another institution) for at least the last 30 days prior to admission
- Ability to understand French or German
- Planned length of stay at least 3 days after enrollment
- For the pilot-study only: Possibility to start the study within 48 hours after admission to the GIM ward
Who cannot join
- Medical contraindication to walk (e.g., wound not allowing loading weight)
- Wheelchair-bound
- End-of-life
- Severe psychiatric disorder (severe depression, schizophrenia, psychosis)
- Delirium (according to the Confusion Assessment Method [CAM])
- Additional exclusion criterion for the pilot-study only:
Show all 10Show fewer
- Dementia (defined as Mini-Cog <3)
- Additional exclusion criteria for the RCT only:
- Cognitive impairment making impossible to use study material (=implement the intervention) and to understand and sign informed consent, based on clinical judgement, except if a proxy can be actively involved in the study and provides consent
- Severe visual impairment
Trial locations and contacts
4 sites in 1 country.
Switzerland4 sites
Kantonsspital Baden
Baden, Canton of Aargau, 5404
Spital Tiefenau, InselGruppe AG
Bern, 3004
Inselspital, Bern University Hospital, InselGruppe AG
Bern, 3010
HFR-Fribourg - hôpital cantonal
Villars-sur-Glâne, Canton of Fribourg, 1752
About this study
Official title: Impact of an INtervention TO Increase MOBility in Older Hospitalized Medical Patients (INTOMOB): a Cluster Randomized Controlled Trial
Low mobility during an acute care hospitalization is very frequent, particularly among older patients, and associated with adverse outcomes, such as persistent functional decline, institutionalization and death. However, increasing hospital mobility remains challenging because of the multiple existing barriers.
The goal of this clinical trial is to test the effect of a multilevel intervention to increase hospital mobility, which addresses modifiable barriers and facilitators and does not require unavailable additional resources.
Read more
This study aims to answer whether this intervention can improve mobility and patient-relevant outcomes such as life-space mobility and functional status.
The multilevel intervention will target:
- The patients, who will receive an information booklet, a customizable diary, an exercise booklet and an iPad with access to the videos of the exercise booklet.
- The healthcare professionals (nursing staff and physicians) who will complete an e-learning, receive an oral presentation on the intervention, and receive a "mobility checklist" that reminds them of what they should assess daily regarding mobility.
- The hospital environment, where posters will be hung in the wards, including walking itineraries, on topics of interest to older adults.
In a first phase, the intervention will be pilot-tested in one ward of each hospital. The intervention will then be adapted based on patient and healthcare professional feedback.
In a second phase, the intervention will be tested in a cluster randomized controlled trial, and compared to standard of care.
- Conditions
- Hospital Mobility, Mobility Limitation, Life-Space, Functional Status, Hospital-Acquired Condition, Muscle Atrophy or Weakness
- Being tested
- INTOMOB intervention
- Keywords
- Hospital mobility, Life-Space, Functional status, Hospital-Acquired disability, Exercise, Movement, Ambulation
- Medical subject headings
- Mobility Limitation, Iatrogenic Disease, Muscular Atrophy, Asthenia, Sarcopenia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
INTOMOB interventionBehavioural
The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:
PATIENTS:
- Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).
- Customizable diary to document mobility goals, results, difficulties and needs.
- Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing).
- iPad 10.2'' with videos of the exercises.
HCPs (physicians \& nursing staff):
- E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation.
- Oral presentation on the intervention.
- Checklist to remind HCPs to address mobility.
ENVIRONMENT:
- Posters in the wards about mobility and other topics of interest to older adults.
- Walking itineraries in the wards.
| Study group | Role | What they receive |
|---|---|---|
| INTOMOB intervention | Experimental | The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment, as described under "Intervention description". Receives: Behavioral: INTOMOB intervention |
| Control | No intervention | Control procedure in the randomized trial: * Patients will receive standard of care, including physiotherapy if prescribed by the hospital physician and usual mobility recommendations and support by the HCPs. * HCPs will neither complete the e-learning, nor receive the checklist and the oral presentation. * The environment will not be modified in regards to mobility. Already existing information on this topic (e.g., small posters hanging in patient rooms) will not be removed, since it corresponds to current standard of care in some hospitals. In the pilot study, there will be no control procedure, since the objective is to assess experience and feasibility of the intervention, not its effects. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Life-space level
Measured by the University of Alabama at Birmingham Study of Aging Life-Space Assessment (range 0-120, with maximum being a higher score = better outcome). For patients institutionalized, assessment through the Life-Space Assessment in Institutionalized Settings. Both scales can be merged since the scoring is similar. Assessment by telephone interview of the participant/relatives.
Measured: Day 30 (+/-5) after enrollment
Secondary outcomes (46)
Life-space level
Measured by the University of Alabama at Birmingham Study of Aging Life-Space Assessment (or Life-Space Assessment in Institutionalized Settings for institutionalized patients) by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Activities of Daily Living
Measured by the Barthel Index by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Activities of Daily Living
Measured by the Barthel Index by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Instrumental Activities of Daily Living
Measured by the Lawton Index by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Instrumental Activities of Daily Living
Measured by the Lawton Index by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Quality of life (EQ-5D)
Measured by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Quality of life (EQ-5D)
Measured by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Depression
Measured by the Patient Health Questionnaire (PHQ)-2 by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Depression
Measured by the Patient Health Questionnaire (PHQ)-2 by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Pressure ulcer
Evaluated according to the NPUAP/EPUAP classification, based on nurse report and electronic health record
Measured: Discharge (-1 to +2 days after discharge)
Delirium during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Measured by the Confusion Assessment Method
Measured: Discharge (-1 to +2 days after discharge)
Mobility at discharge
Measured by the de Morton Mobility Index (DEMMI); assessment conducted by the study team
Measured: Discharge (maximum 1 day before)
Lower-limb muscle strength
Measured by lower-limb manual testing according to the method by Hislop and Montgomery; assessment conducted by the study team
Measured: Discharge (maximum 1 day before)
Hand-grip muscle strength
Measured by JAMAR (for the pilot study) and SAEHAN (for the RCT) hand dynamometer; assessment conducted by the study team
Measured: Discharge (maximum 1 day before)
Step count during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Measured by a StepWatch ankle accelerometer or a GENEActiv wrist accelerometer (the choice of the device will be defined after the pilot study during which both accelerometers will be tested)
Measured: Discharge (hospitalization duration expected to be 3 to 20 days on average)
Level of activity during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Measured by GENEActiv wrist accelerometer (only if this accelerometer is chosen after the pilot study)
Measured: Discharge (hospitalization duration expected to be 3 to 20 days on average)
Fear of / concerns about falling
Measured by the Falls Efficacy Scale - International by telephone interview of the participant/relatives
Measured: Discharge (-1 to +2 days after discharge)
Fear of / concerns about falling
Measured by the Falls Efficacy Scale - International by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Fear of / concerns about falling
Measured by the Falls Efficacy Scale - International by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Fall-risk increasing drugs
Including loop diuretic, beta blocker, cardiac glycoside (digitalis, digoxin), statin, antipsychotic (neuroleptic), tricyclic antidepressant, selective serotonin reuptake inhibitor, other antidepressant, benzodiazepine, opioid, antiepileptic. Assessed through the electronic health record
Measured: Discharge (discharge letter) (hospitalization duration expected to be 3 to 20 days on average)
Fall-risk increasing drugs during hospitalization
Including loop diuretic, beta blocker, cardiac glycoside (digitalis, digoxin), statin, antipsychotic (neuroleptic), tricyclic antidepressant, selective serotonin reuptake inhibitor, other antidepressant, benzodiazepine, opioid, antiepileptic. Assessed through the electronic health record
Measured: Discharge (discharge letter) (hospitalization duration expected to be 3 to 20 days on average)]
Fall-risk increasing drugs
Including loop diuretic, beta blocker, cardiac glycoside (digitalis, digoxin), statin, antipsychotic (neuroleptic), tricyclic antidepressant, selective serotonin reuptake inhibitor, other antidepressant, benzodiazepine, opioid, antiepileptic. Assessed by telephone interview of the participant
Measured: Day 30 (+/-5) after enrollment
Fall-risk increasing drugs
Including loop diuretic, beta blocker, cardiac glycoside (digitalis, digoxin), statin, antipsychotic (neuroleptic), tricyclic antidepressant, selective serotonin reuptake inhibitor, other antidepressant, benzodiazepine, opioid, antiepileptic. Assessed by telephone interview of the participant
Measured: Day 180 (+/-5) after enrollment
Number of patients with fall(s) during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Based on nurse report and electronic health record data
Measured: Discharge (-1 to +2 days after discharge)
Number of falls per patient during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Based on nurse report and electronic health record data
Measured: Discharge (-1 to +2 days after discharge)
Number of patients with fall(s) within 30 days after discharge
Assessed by telephone interview of the participant/relatives, based on a diary the participants/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of falls per patient within 30 days after discharge
Assessed by telephone interview of the participant/relatives, based on a diary the participants/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of patients with fall(s) within 180 days after discharge
Assessed by telephone interview of the participant/relatives, based on a diary the participants/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Number of falls per patient within 180 days after discharge
Assessed by telephone interview of the participant/relatives, based on a diary the participants/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Number of patients with new institutionalization at discharge
According to nurses / electronic health record / self-report by participant/relatives
Measured: Discharge (-1 to +2 days after discharge)
Number of patients with new institutionalization within 30 days of discharge
Assessed by telephone interview of the participant/relatives
Measured: Day 30 (+/-5) after enrollment
Number of patients with new institutionalization within 180 days of discharge
Assessed by telephone interview of the participant/relatives
Measured: Day 180 (+/-5) after enrollment
Number of patients with emergency room visits within 30 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of emergency room visits per patient within 30 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of patients with emergency room visits within 180 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Number of emergency room visits per patient within 180 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Number of patients with readmission within 30 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of readmissions per patient within 30 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 30 (+/-5) after enrollment
Number of patients with readmission within 180 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Number of readmissions per patient within 180 days of discharge
Assessed based on electronic health record and by telephone interview of the participant/relatives, based on the diary the participant/relatives will be asked to complete.
Measured: Day 180 (+/-5) after enrollment
Experience of the intervention
Assessed through qualitative and quantitative questions by interview of the participants/relatives (on the ward or by telephone). For the intervention group only. Will be done at the end of the assessment to preserve outcome assessor blinding.
Measured: Discharge (-1 to +2 days after discharge)
Satisfaction with hospitalization
Measured by the satisfaction questionnaire adapted and simplified
Measured: Discharge (-1 to +2 days after discharge)
Perspectives on hospital mobility
Quantitative questions (Likert-scale answers) based on the Health Action Process Approach (HAPA) model (simplification of a survey used in the preparation phase of this study to assess perspectives of patients and healthcare professionals on hospital mobility).
Measured: Day 30 (+/-5) after enrollment
Location at follow-up
Assessed by telephone interview of patient/relatives.
Measured: Day 30 (+/-5) after enrollment
Location at follow-up
Assessed by telephone interview of patient/relatives.
Measured: Day 180 (+/-5) after enrollment
Discharge destination
Assessed based on electronic health records
Measured: Discharge (-1 to +2 days after discharge)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2022
- Study start15 Dec 2022
- Primary completion18 Jul 2025
- Study completion18 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hospital MobilityStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- In a first phase, the intervention will be pilot-tested in one ward of each hospital (no comparison group). In a second phase, it will be tested in a parallel design (cluster randomized controlled trial).
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 383 participants (actual)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Collaborators
- Swiss National Science Foundation, Hôpital Fribourgeois, Kantonsspital Baden
- Responsible party
- Sponsor
- Investigators
- Carole E Aubert, MD, MSc, Principal investigator, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05639231
- Sponsor's protocol ID
- 2022-01568
- Acronym
- INTOMOB
- Status last verified
- Aug 2025
- First submitted
- 28 Nov 2022
- Last updated
- 12 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Study protocol, statistical analysis plan, informed consent form will be published. Other data will be made available upon reasonable request.
Publications
Mooser B, Bergsma D, Liechti FD, Baumgartner C, Gentizon J, Mean M, Wertli MM, Mancinetti M, Schmidt-Leuenberger J, Aubert CE. Impact of an INtervention to increase MOBility in older hospitalized medical patients (INTOMOB): Study protocol for a cluster randomized controlled trial. BMC Geriatr. 2023 Oct 31;23(1):705. doi: 10.1186/s12877-023-04285-3.
PubMed 37907858
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of an INtervention TO Increase MOBility in Older Hospitalized Medical Patients (INTOMOB): a Cluster Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05639231
- Acronym / sponsor ID
- INTOMOB / 2022-01568
- Conditions
- Hospital Mobility, Mobility Limitation, Life-Space, Functional Status, Hospital-Acquired Condition, Muscle Atrophy or Weakness
- Keywords
- Hospital mobility, Life-Space, Functional status, Hospital-Acquired disability, Exercise, Movement, Ambulation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 383 participants (actual)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Collaborators
- Swiss National Science Foundation, Hôpital Fribourgeois, Kantonsspital Baden
- Study start
- 15 Dec 2022 (actual)
- Primary completion
- 18 Jul 2025 (actual)
- Study completion
- 18 Jul 2025 (actual)
- First posted
- 6 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low mobility during an acute care hospitalization is very frequent, particularly among older patients, and associated with adverse outcomes, such as persistent functional decline, institutionalization and death. However, increasing hospital mobility remains challenging because of the multiple existing barriers.
The goal of this clinical trial is to test the effect of a multilevel intervention to increase hospital mobility, which addresses modifiable barriers and facilitators and does not require unavailable additional resources.
This study aims to answer whether this intervention can improve mobility and patient-relevant outcomes such as life-space mobility and functional status.
The multilevel intervention will target:
- The patients, who will receive an information booklet, a customizable diary, an exercise booklet and an iPad with access to the videos of the exercise booklet.
- The healthcare professionals (nursing staff and physicians) who will complete an e-learning, receive an oral presentation on the intervention, and receive a "mobility checklist" that reminds them of what they should assess daily regarding mobility.
- The hospital environment, where posters will be hung in the wards, including walking itineraries, on topics of interest to older adults.
In a first phase, the intervention will be pilot-tested in one ward of each hospital. The intervention will then be adapted based on patient and healthcare professional feedback.
In a second phase, the intervention will be tested in a cluster randomized controlled trial, and compared to standard of care.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- In a first phase, the intervention will be pilot-tested in one ward of each hospital (no comparison group). In a second phase, it will be tested in a parallel design (cluster randomized controlled trial).
| Arm | Type | Receives |
|---|---|---|
| INTOMOB intervention | Experimental | Behavioral: INTOMOB interventionThe intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment, as described under "Intervention description". |
| Control | No intervention | –Control procedure in the randomized trial: * Patients will receive standard of care, including physiotherapy if prescribed by the hospital physician and usual mobility recommendations and support by the HCPs. * HCPs will neither complete the e-learning, nor receive the checklist and the oral presentation. * The environment will not be modified in regards to mobility. Already existing information on this topic (e.g., small posters hanging in patient rooms) will not be removed, since it corresponds to current standard of care in some hospitals. In the pilot study, there will be no control procedure, since the objective is to assess experience and feasibility of the intervention, not its effects. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Admission to a general internal medicine (GIM) ward of a participating hospital
- Age ≥60 years
- Being ambulatory during the 2 weeks before admission (self-report)
- Living in the community (not in a nursing home or another institution) for at least the last 30 days prior to admission
- Ability to understand French or German
Key exclusion criteria (10 listed)
- Medical contraindication to walk (e.g., wound not allowing loading weight)
- Wheelchair-bound
- End-of-life
- Severe psychiatric disorder (severe depression, schizophrenia, psychosis)
- Delirium (according to the Confusion Assessment Method [CAM])
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| INTOMOB interventionThe intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment: PATIENTS: * Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information). * Customizable diary to document mobility goals, results, difficulties and needs. * Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing). * iPad 10.2'' with videos of the exercises. HCPs (physicians \& nursing staff): * E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation. * Oral presentation on the intervention. * Checklist to remind HCPs to address mobility. ENVIRONMENT: * Posters in the wards about mobility and other topics of interest to older adults. * Walking itineraries in the wards. | Behavioural | INTOMOB intervention |
Primary outcome
Life-space level
Time frame: Day 30 (+/-5) after enrollment
Measured by the University of Alabama at Birmingham Study of Aging Life-Space Assessment (range 0-120, with maximum being a higher score = better outcome). For patients institutionalized, assessment through the Life-Space Assessment in Institutionalized Settings. Both scales can be merged since the scoring is similar. Assessment by telephone interview of the participant/relatives.
46 secondary outcomes
Life-space level
Time frame: Day 180 (+/-5) after enrollment
Activities of Daily Living
Time frame: Day 30 (+/-5) after enrollment
Activities of Daily Living
Time frame: Day 180 (+/-5) after enrollment
Instrumental Activities of Daily Living
Time frame: Day 30 (+/-5) after enrollment
Instrumental Activities of Daily Living
Time frame: Day 180 (+/-5) after enrollment
Quality of life (EQ-5D)
Time frame: Day 30 (+/-5) after enrollment
Quality of life (EQ-5D)
Time frame: Day 180 (+/-5) after enrollment
Depression
Time frame: Day 30 (+/-5) after enrollment
Depression
Time frame: Day 180 (+/-5) after enrollment
Pressure ulcer
Time frame: Discharge (-1 to +2 days after discharge)
Delirium during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Time frame: Discharge (-1 to +2 days after discharge)
Mobility at discharge
Time frame: Discharge (maximum 1 day before)
Lower-limb muscle strength
Time frame: Discharge (maximum 1 day before)
Hand-grip muscle strength
Time frame: Discharge (maximum 1 day before)
Step count during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Time frame: Discharge (hospitalization duration expected to be 3 to 20 days on average)
Level of activity during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Time frame: Discharge (hospitalization duration expected to be 3 to 20 days on average)
Fear of / concerns about falling
Time frame: Discharge (-1 to +2 days after discharge)
Fear of / concerns about falling
Time frame: Day 30 (+/-5) after enrollment
Fear of / concerns about falling
Time frame: Day 180 (+/-5) after enrollment
Fall-risk increasing drugs
Time frame: Discharge (discharge letter) (hospitalization duration expected to be 3 to 20 days on average)
Fall-risk increasing drugs during hospitalization
Time frame: Discharge (discharge letter) (hospitalization duration expected to be 3 to 20 days on average)]
Fall-risk increasing drugs
Time frame: Day 30 (+/-5) after enrollment
Fall-risk increasing drugs
Time frame: Day 180 (+/-5) after enrollment
Number of patients with fall(s) during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Time frame: Discharge (-1 to +2 days after discharge)
Number of falls per patient during hospitalization (hospitalization duration expected to be 3 to 20 days on average)
Time frame: Discharge (-1 to +2 days after discharge)
Number of patients with fall(s) within 30 days after discharge
Time frame: Day 30 (+/-5) after enrollment
Number of falls per patient within 30 days after discharge
Time frame: Day 30 (+/-5) after enrollment
Number of patients with fall(s) within 180 days after discharge
Time frame: Day 180 (+/-5) after enrollment
Number of falls per patient within 180 days after discharge
Time frame: Day 180 (+/-5) after enrollment
Number of patients with new institutionalization at discharge
Time frame: Discharge (-1 to +2 days after discharge)
Number of patients with new institutionalization within 30 days of discharge
Time frame: Day 30 (+/-5) after enrollment
Number of patients with new institutionalization within 180 days of discharge
Time frame: Day 180 (+/-5) after enrollment
Number of patients with emergency room visits within 30 days of discharge
Time frame: Day 30 (+/-5) after enrollment
Number of emergency room visits per patient within 30 days of discharge
Time frame: Day 30 (+/-5) after enrollment
Number of patients with emergency room visits within 180 days of discharge
Time frame: Day 180 (+/-5) after enrollment
Number of emergency room visits per patient within 180 days of discharge
Time frame: Day 180 (+/-5) after enrollment
Number of patients with readmission within 30 days of discharge
Time frame: Day 30 (+/-5) after enrollment
Number of readmissions per patient within 30 days of discharge
Time frame: Day 30 (+/-5) after enrollment
Number of patients with readmission within 180 days of discharge
Time frame: Day 180 (+/-5) after enrollment
Number of readmissions per patient within 180 days of discharge
Time frame: Day 180 (+/-5) after enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2025.
- Derived from this study: PubMed 37907858Mooser B, Bergsma D, Liechti FD, Baumgartner C, Gentizon J, Mean M, Wertli MM, Mancinetti M, Schmidt-Leuenberger J, Aubert CE. Impact of an INtervention to increase MOBility in older hospitalized medical patients (INTOMOB): Study protocol for a cluster randomized controlled trial. BMC Geriatr. 2023 Oct 31;23(1):705. doi: 10.1186/s12877-023-04285-3.
- Individual participant dataSharing planned: Yes. Study protocol, statistical analysis plan, informed consent form will be published. Other data will be made available upon reasonable request.
Related trials for Hospital Mobility
Recruiting
Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients
Mobility Limitation, Frailty
Not yet recruitingObservational study
Physical Activity During Hospitalization and Hospital-Associated Disability
Acute Disease, Old Age
Not yet recruitingObservational study
An Observational, Multinational, In Hospital Evaluation of Catheter Utilization Rates in Female Patients Using Indwelling Urinary Catheters and the PureWick™ Flex Female External Catheter Across Europe and the Middle East
Urinary Incontinence, Limited Mobility
Recruiting
Influence of the Culture Care Program on Patient Mobility After Thoracic or Abdominal Surgery: a Mixed-methods Study
Thoracic Surgery, Abdominal Surgery Patients
Not yet recruitingEarly Phase 1
Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors
Critical Illness, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carole E Aubert, MD, MSc principal investigator
Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing INTOMOB intervention in people with Hospital Mobility and Mobility Limitation, run by Insel Gruppe AG, University Hospital Bern at 4 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Life-space level (time frame: Day 30 (+/-5) after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05639231, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2025.